Nanobiotix (NBTX) - Total Liabilities
Based on the latest financial reports, Nanobiotix (NBTX) has total liabilities worth $152.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanobiotix - Total Liabilities Trend (2011–2025)
This chart illustrates how Nanobiotix's total liabilities have evolved over time, based on quarterly financial data. See Nanobiotix (NBTX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Nanobiotix Competitors by Total Liabilities
The table below lists competitors of Nanobiotix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
China | CN¥125.45 Billion |
|
Yuan Longping High-tech Agriculture Co Ltd
SHE:000998
|
China | CN¥14.59 Billion |
|
Jiangsu Linyang Energy Co Ltd
SHG:601222
|
China | CN¥8.84 Billion |
|
Austevoll Seafood ASA
OL:AUSS
|
Norway | Nkr24.24 Billion |
|
Jiangsu Expressway Company Limited
F:JE2
|
Germany | €42.78 Billion |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
USA | $899.65 Million |
|
Ruentex Industries Ltd
TW:2915
|
Taiwan | NT$13.26 Billion |
|
SJW Group Common Stock
NYSE:SJW
|
USA | $3.33 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Nanobiotix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nanobiotix (NBTX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanobiotix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanobiotix (2011–2025)
The table below shows the annual total liabilities of Nanobiotix from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.24 Million | +14.36% |
| 2024-12-31 | $133.12 Million | +39.04% |
| 2023-12-31 | $95.74 Million | +10.28% |
| 2022-12-31 | $86.81 Million | +15.78% |
| 2021-12-31 | $74.98 Million | +17.96% |
| 2020-12-31 | $63.56 Million | +9.37% |
| 2019-12-31 | $58.11 Million | +81.88% |
| 2018-12-31 | $31.95 Million | +135.90% |
| 2017-12-31 | $13.54 Million | +4.15% |
| 2016-12-31 | $13.00 Million | +20.33% |
| 2015-12-31 | $10.81 Million | +60.38% |
| 2014-12-31 | $6.74 Million | +58.29% |
| 2013-12-31 | $4.26 Million | +27.93% |
| 2012-12-31 | $3.33 Million | +67.40% |
| 2011-12-31 | $1.99 Million | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more